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Abstract
Current therapy of a number of neuropsychiatric maladies has only symptomatic modality.
Effective treatment of these neurodegenerative diseases, including amyotrophic lateral sclerosis
(ALS),  may benefit  from combined gene/stem-cell  approaches.  In  this  report,  mononuclear
fraction of human umbilical cord blood cells (hUCBCs) were transfected by electroporation with
dual  plasmid  constructs,  simultaneously  expressing  vascular  endothelial  growth factor  165
(VEGF165) and human fibroblast growth factor 2 (FGF2) (pBud-VEGF-FGF2). These genetically
modified  hUCBCs  were  injected  retro-orbitally  into  presymptomatic  ALS  transgenic  animal
models ( G93A mice). Lumbar spinal cords of rodents were processed for immunofluoresent
staining with antibodies against human nuclear antigen (HNA), oligodendrocyte-specific protein,
S100, iba1, neuronal β3-tubulin and CD34. Co-localization of HNA and S100 was found in the
spinal cord of mice after transplantation of genetically modified hUCBCs over-expressing VEGF-
FGF2. Double staining in control animals treated with unmodified hUCBCs, however, revealed
HNA+ cells expressing iba1 and CD34. Neuron-specific β3-tubulin or oligodendrocyte-specific
protein were not expressed in hUCBCs in either control or experimental mice. These results
demonstrate that genetically naïve hUCBCs may differentiate into endothelial  (CD34+) and
microglial  (iba1+) cells;  however when over-expressing VEGF-FGF2,  hUCBCs transform into
astrocytes (S100+). Autocrine regulation of VEGF and FGF2 on hUCBCs, signal molecules from
dying motor neurons in spinal cord, as well as self-differentiating potential may provide a unique
microenvironment for the transformation of hUCBCs into astrocytes that eventually serve as a
source of growth factors to enhance the survive potential of surrounding cells in the diseased
regions. Copyright © 2011 by the Society for Experimental Biology and Medicine.
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